<?xml version='1.0' encoding='utf-8'?>
<document id="24997757"><sentence text="Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate."><entity charOffset="46-63" id="DDI-PubMed.24997757.s1.e0" text="ethinyl estradiol" /><entity charOffset="68-77" id="DDI-PubMed.24997757.s1.e1" text="gestodene" /><pair ddi="false" e1="DDI-PubMed.24997757.s1.e0" e2="DDI-PubMed.24997757.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24997757.s1.e0" e2="DDI-PubMed.24997757.s1.e1" /></sentence><sentence text="Pharmacokinetic (PK) interactions between the cytochrome P450 3A4 (CYP3A4) pathway and transdermally administered ethinyl estradiol (EE) and gestodene (GSD) were investigated"><entity charOffset="114-131" id="DDI-PubMed.24997757.s2.e0" text="ethinyl estradiol" /><entity charOffset="133-135" id="DDI-PubMed.24997757.s2.e1" text="EE" /><entity charOffset="141-150" id="DDI-PubMed.24997757.s2.e2" text="gestodene" /><entity charOffset="152-155" id="DDI-PubMed.24997757.s2.e3" text="GSD" /><pair ddi="false" e1="DDI-PubMed.24997757.s2.e0" e2="DDI-PubMed.24997757.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24997757.s2.e0" e2="DDI-PubMed.24997757.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24997757.s2.e0" e2="DDI-PubMed.24997757.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24997757.s2.e0" e2="DDI-PubMed.24997757.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24997757.s2.e1" e2="DDI-PubMed.24997757.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24997757.s2.e1" e2="DDI-PubMed.24997757.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24997757.s2.e1" e2="DDI-PubMed.24997757.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24997757.s2.e2" e2="DDI-PubMed.24997757.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24997757.s2.e2" e2="DDI-PubMed.24997757.s2.e3" /></sentence><sentence text=" This paper reports the findings of three open-label, intra-individual, one-way crossover, Phase I trials" /><sentence text=" In two studies, women used a novel contraceptive patch for 3 weeks during two 4-week study periods; in the second period, the CYP3A4 inhibitors erythromycin (Study 1) or ketoconazole (Study 2) were administered concurrently"><entity charOffset="145-157" id="DDI-PubMed.24997757.s4.e0" text="erythromycin" /><entity charOffset="171-183" id="DDI-PubMed.24997757.s4.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.24997757.s4.e0" e2="DDI-PubMed.24997757.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24997757.s4.e0" e2="DDI-PubMed.24997757.s4.e1" /></sentence><sentence text=" In a third study, women received single doses of the CYP3A4 model substrate midazolam, alone and after 3 weeks of concurrent patch application" /><sentence text=" In each period, the EE/GSD patch (delivering low EE and GSD doses resulting in the same systemic exposure as a combined oral contraceptive containing 0"><entity charOffset="21-32" id="DDI-PubMed.24997757.s6.e0" text="EE" /><entity charOffset="50-61" id="DDI-PubMed.24997757.s6.e1" text="EE" /><entity charOffset="24-35" id="DDI-PubMed.24997757.s6.e2" text="GSD" /><entity charOffset="57-68" id="DDI-PubMed.24997757.s6.e3" text="GSD" /><pair ddi="false" e1="DDI-PubMed.24997757.s6.e0" e2="DDI-PubMed.24997757.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24997757.s6.e0" e2="DDI-PubMed.24997757.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24997757.s6.e0" e2="DDI-PubMed.24997757.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24997757.s6.e0" e2="DDI-PubMed.24997757.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24997757.s6.e2" e2="DDI-PubMed.24997757.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24997757.s6.e2" e2="DDI-PubMed.24997757.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24997757.s6.e2" e2="DDI-PubMed.24997757.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24997757.s6.e1" e2="DDI-PubMed.24997757.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24997757.s6.e1" e2="DDI-PubMed.24997757.s6.e3" /></sentence><sentence text="02 mg EE and 0"><entity charOffset="6-8" id="DDI-PubMed.24997757.s7.e0" text="EE" /></sentence><sentence text="06 mg GSD) was applied once weekly for 3 weeks, with one patch-free week"><entity charOffset="6-7" id="DDI-PubMed.24997757.s8.e0" text="GSD" /></sentence><sentence text=" Erythromycin, ketoconazole, and midazolam were administered orally"><entity charOffset="1-13" id="DDI-PubMed.24997757.s9.e0" text="Erythromycin" /><entity charOffset="15-27" id="DDI-PubMed.24997757.s9.e1" text="ketoconazole" /><entity charOffset="33-42" id="DDI-PubMed.24997757.s9.e2" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.24997757.s9.e0" e2="DDI-PubMed.24997757.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24997757.s9.e0" e2="DDI-PubMed.24997757.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24997757.s9.e0" e2="DDI-PubMed.24997757.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24997757.s9.e1" e2="DDI-PubMed.24997757.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24997757.s9.e1" e2="DDI-PubMed.24997757.s9.e2" /></sentence><sentence text=" Main outcome measures were area under the curves (AUCs) and maximum plasma concentration (C max) of EE, and total and unbound GSD (Studies 1 and 2)"><entity charOffset="101-109" id="DDI-PubMed.24997757.s10.e0" text="EE" /><entity charOffset="127-135" id="DDI-PubMed.24997757.s10.e1" text="GSD" /><pair ddi="false" e1="DDI-PubMed.24997757.s10.e0" e2="DDI-PubMed.24997757.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24997757.s10.e0" e2="DDI-PubMed.24997757.s10.e1" /></sentence><sentence text=" AUC and C max of midazolam (Study 3)" /><sentence text=" Co-administration of CYP3A4 inhibitors did not affect EE metabolism, and had only weak effects on the PK of total and unbound GSD"><entity charOffset="55-57" id="DDI-PubMed.24997757.s12.e0" text="EE" /><entity charOffset="127-129" id="DDI-PubMed.24997757.s12.e1" text="GSD" /><pair ddi="false" e1="DDI-PubMed.24997757.s12.e0" e2="DDI-PubMed.24997757.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24997757.s12.e0" e2="DDI-PubMed.24997757.s12.e1" /></sentence><sentence text=" The patch had no clinically relevant effect on metabolism of the CYP3A4 substrate midazolam" /><sentence text=" " /></document>